Felipe Cardenal

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

Corinne Faivre‐Finn, M. Snee, Linda Ashcroft et al. · The Lancet Oncology · 2017 · 570 citations · Full text

Medicine, Oncology, Radiation Oncology +15

Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

Felipe Cardenal, M.P. López-Cabrerizo, Antonio Antón et al. · Journal of Clinical Oncology · 1999 · 476 citations

Medicine, Oncology, Pharmacology +10

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

Daniel D. Karp, Luis Paz‐Ares, Silvia Novello et al. · Journal of Clinical Oncology · 2009 · 262 citations · Full text

Medicine, Oncology, Pharmacology +17

Association of<i>EGFR</i>L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Niki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt et al. · JAMA Oncology · 2015 · 238 citations · Full text

Medicine, Molecular Biology, Oncology +17

KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma

Ernest Nadal, Guoan Chen, John R. Prensner et al. · Journal of Thoracic Oncology · 2014 · 141 citations · Full text

Medicine, Genetics, Oncology +12